Gene
MYCN
MYCN is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (40), Actionable biomarkers (1), Trial mentions (105), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MYCN. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 3 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 11 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 4 of 8,738 | 0.05% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 6 of 8,597 | 0.07% | not measured | |
| 2023 | 5 of 8,275 | 0.06% | 14 of 11,460 | 0.12% |
| 2022 | 3 of 8,285 | 0.04% | 26 of 13,598 | 0.19% |
| 2021 | 4 of 8,692 | 0.05% | 32 of 15,045 | 0.21% |
| 2020 | 2 of 7,640 | 0.03% | 32 of 14,459 | 0.22% |
| 2019 | 4 of 7,300 | 0.05% | 23 of 12,159 | 0.19% |
| 2018 | 2 of 6,927 | 0.03% | 28 of 11,854 | 0.24% |
| 2017 | 3 of 6,558 | 0.05% | 20 of 11,595 | 0.17% |
Showing 10 of 37 years.
Assay-provider ledger (40)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| GenePlus Co., Ltd. | Diagnostic provider | No clinical or analytical validation recorded for this pair | 1 | November 01, 2021 |
| Broad Institute | Not a company | Analytical validation | 1 | December 20, 2019 |
| Open Targets | Not a company | Analytical validation | 1 | December 20, 2019 |
| Wellcome Sanger Institute | Not a company | Analytical validation | 1 | December 20, 2019 |
| Horizon Discovery | Reagent supplier | Clinical validationAnalytical validation | 1 | November 01, 2019 |
Showing 5 of 40 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MYCN amplification | Smo Inhibitors | responsive | medulloblastoma | Cancer Genome Interpreter |
Trial mentions (105)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01505569 | Trial eligibility (AACT) |
| NCT06858501 | Trial eligibility (AACT) |
| NCT04221035 | Trial eligibility (AACT) |
| NCT04696029 | Trial eligibility (AACT) |
| NCT01589341 | Trial eligibility (AACT) |
Showing 5 of 105 trial mentions.
Target-disease associations (451)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 25-hydroxyvitamin D3 measurement | measurement | GWAS credible sets |
| Abnormality of mental function | phenotype | GWAS credible sets |
| Abnormality of refraction | phenotype | GWAS credible sets |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 451 associations.
Vendor sourcing (311)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This missense variant is not observed in the gnomAD v2.1.1 dataset. In silico tool predictions suggest damaging effect of the variant on gene or gene product... | View ClinVar record SCV002572824.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The alteration results in an amino acid change:_x000D_ _x000D_ The c.1177C>T (p.R393C) alteration is located in exon 3 (coding exon 2) of the MYCN gene. This... | View ClinVar record SCV001444305.4 |
| Astrazeneca Plc | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Known severe hypersensitivity to ZD1839 or any of the excipients of this product * Any evidence, as judged by the investigator, of severe or uncontrolle... | View trial NCT00135135 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | MYCN | View trial NCT00135135 |
| Astrazeneca Plc | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | for all Modules: 1. Metastatic MIBC 2. 2nd/3rd line 3. Failed adjuvant/neo-adjuvant chemotherapy \<1 yr 4. 1 lesion ≥10 mm at baseline in the longest diamet... | View trial NCT02546661 |
Showing 5 of 311 sourcing records.
Trial-cited literature (351)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | JCO precision oncology | 2026 | 0 |
| A simple guide to the use of Student's t-test, Mann-Whitney U test, Chi-squared test, and Kruskal-Wallis test in biostatistics. | BioData mining | 2025 | 35 |
| A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | 9 |
| A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. | Cancer medicine | 2025 | 4 |
| Chemo-Immunotherapy Rescue for High-Risk Neuroblastoma Patients With Progressive Disease Before High-Dose Chemotherapy: Real-World Data From the SACHA-France Study. | Pediatric blood & cancer | 2025 | 3 |
Showing 5 of 351 papers.
Protein variant mentions (18)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A165D | 1 | 2015 | PMID 25741868 |
| p.E93D | 1 | 2015 | PMID 25741868 |
| p.F10A | 1 | 2010 | PMID 20049927 |
| p.F16A | 1 | 2010 | PMID 20049927 |
| p.F24C | 1 | 2020 | PMID 33199677 |
Showing 5 of 18 variants.
Literature-extracted relations (132)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Eflornithine | Chemical | negative_correlate |
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. | 2024 |
| TOPOTECAN | Chemical | negative_correlate |
A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. | 2012 |
| Neoplasms | Disease | associate |
Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | 2026 |
| Rhabdomyosarcoma, Embryonal | Disease | associate |
Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | 2026 |
| Neuroblastoma | Disease | associate |
A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. | 2025 |
Showing 5 of 132 relation assertions.
Organizations publishing (442)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 28 | 2009 to 2025 |
| Children's Hospital of Philadelphia | Hospital | 24 | 1993 to 2025 |
| Novant Health | Hospital | 23 | 1991 to 2023 |
| University of Cologne | Academic | 18 | 2003 to 2023 |
| Government of the United States of America | Government | 17 | 2015 to 2023 |
Showing 5 of 442 organizations.
Where MYCN appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- infectious disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
402 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.